Literature DB >> 22138189

Hepatitis C virus infects the endothelial cells of the blood-brain barrier.

Nicola F Fletcher1, Garrick K Wilson, Jacinta Murray, Ke Hu, Andrew Lewis, Gary M Reynolds, Zania Stamataki, Luke W Meredith, Ian A Rowe, Guangxiang Luo, Miguel A Lopez-Ramirez, Thomas F Baumert, Babette Weksler, Pierre-Olivier Couraud, Kwang Sik Kim, Ignacio A Romero, Catherine Jopling, Susan Morgello, Peter Balfe, Jane A McKeating.   

Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) infection leads to progressive liver disease and is associated with a variety of extrahepatic syndromes, including central nervous system (CNS) abnormalities. However, it is unclear whether such cognitive abnormalities are a function of systemic disease, impaired hepatic function, or virus infection of the CNS.
METHODS: We measured levels of HCV RNA and expression of the viral entry receptor in brain tissue samples from 10 infected individuals (and 3 uninfected individuals, as controls) and human brain microvascular endothelial cells by using quantitative polymerase chain reaction and immunochemical and confocal imaging analyses. HCV pseudoparticles and cell culture-derived HCV were used to study the ability of endothelial cells to support viral entry and replication.
RESULTS: Using quantitative polymerase chain reaction, we detected HCV RNA in brain tissue of infected individuals at significantly lower levels than in liver samples. Brain microvascular endothelia and brain endothelial cells expressed all of the recognized HCV entry receptors. Two independently derived brain endothelial cell lines, hCMEC/D3 and HBMEC, supported HCV entry and replication. These processes were inhibited by antibodies against the entry factors CD81, scavenger receptor BI, and claudin-1; by interferon; and by reagents that inhibit NS3 protease and NS5B polymerase. HCV infection promotes endothelial permeability and cellular apoptosis.
CONCLUSIONS: Human brain endothelial cells express functional receptors that support HCV entry and replication. Virus infection of the CNS might lead to HCV-associated neuropathologies. Copyright Â
© 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138189      PMCID: PMC3801216          DOI: 10.1053/j.gastro.2011.11.028

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  42 in total

1.  Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.

Authors:  Catherine L Jopling; Minkyung Yi; Alissa M Lancaster; Stanley M Lemon; Peter Sarnow
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

Review 2.  Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus.

Authors:  Susanne Kramer-Hämmerle; Ina Rothenaigner; Horst Wolff; Jeanne E Bell; Ruth Brack-Werner
Journal:  Virus Res       Date:  2005-08       Impact factor: 3.303

3.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones.

Authors:  Anja Zensi; David Begley; Charles Pontikis; Celine Legros; Larisa Mihoreanu; Sylvia Wagner; Claudia Büchel; Hagen von Briesen; Jörg Kreuter
Journal:  J Control Release       Date:  2009-03-11       Impact factor: 9.776

Review 4.  The blood-brain barrier: an overview: structure, regulation, and clinical implications.

Authors:  Praveen Ballabh; Alex Braun; Maiken Nedergaard
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

5.  Visualizing hepatitis C virus infections in human liver by two-photon microscopy.

Authors:  Yuqiong Liang; Tuya Shilagard; Shu-Yuan Xiao; Ned Snyder; Daryl Lau; Luca Cicalese; Heidi Weiss; Gracie Vargas; Stanley M Lemon
Journal:  Gastroenterology       Date:  2009-07-24       Impact factor: 22.682

Review 6.  Role of lipid metabolism in hepatitis C virus assembly and entry.

Authors:  Costin-Ioan Popescu; Jean Dubuisson
Journal:  Biol Cell       Date:  2009-10-28       Impact factor: 4.458

7.  Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.

Authors:  Sophie E Krieger; Mirjam B Zeisel; Christopher Davis; Christine Thumann; Helen J Harris; Eva K Schnober; Christopher Mee; Eric Soulier; Cathy Royer; Mélanie Lambotin; Fritz Grunert; Viet Loan Dao Thi; Marlène Dreux; François-Loïc Cosset; Jane A McKeating; Catherine Schuster; Thomas F Baumert
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

8.  The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies.

Authors:  Birk Poller; Heike Gutmann; Stephan Krähenbühl; Babette Weksler; Ignacio Romero; Pierre-Olivier Couraud; Gerald Tuffin; Jürgen Drewe; Jörg Huwyler
Journal:  J Neurochem       Date:  2008-12       Impact factor: 5.372

9.  Hepatitis C virus neuroinvasion: identification of infected cells.

Authors:  Jeffrey Wilkinson; Marek Radkowski; Tomasz Laskus
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

10.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

View more
  79 in total

1.  Hepatitis: Brain endothelial cells support HCV entry and replication.

Authors:  Isobel Franks
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 46.802

Review 2.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

3.  S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder.

Authors:  Jennifer M Loftis; Juno Valerio; Jonathan Taylor; Elaine Huang; Rebekah Hudson; Patricia Taylor-Young; Michael Chang; Samuel B Ho; Eric Dieperink; Juan Luis Miranda; Peter Hauser
Journal:  Alcohol Clin Exp Res       Date:  2018-06-28       Impact factor: 3.455

4.  Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis.

Authors:  Helal F Hetta; Mohamed A Mekky; Nasr K Khalil; Wegdan A Mohamed; Mohamed A El-Feky; Shabaan H Ahmed; Enas A Daef; Ahmed Medhat; Mahmoud I Nassar; Kenneth E Sherman; Mohamed Tarek M Shata
Journal:  J Med Microbiol       Date:  2016-05-10       Impact factor: 2.472

Review 5.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

6.  Impact of infection on risk of Parkinson's disease: a quantitative assessment of case-control and cohort studies.

Authors:  Lei Meng; Liang Shen; Hong-Fang Ji
Journal:  J Neurovirol       Date:  2019-01-10       Impact factor: 2.643

Review 7.  Virus infections in the nervous system.

Authors:  Orkide O Koyuncu; Ian B Hogue; Lynn W Enquist
Journal:  Cell Host Microbe       Date:  2013-04-17       Impact factor: 21.023

8.  Unexpected maintenance of hepatitis C viral diversity following liver transplantation.

Authors:  Rebecca R Gray; Samantha L Strickland; Nazle M Veras; Maureen M Goodenow; Oliver G Pybus; Stanley M Lemon; Michael W Fried; David R Nelson; Marco Salemi
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 9.  Vasculitis: determinants of disease patterns.

Authors:  Gary S Hoffman; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2014-06-17       Impact factor: 20.543

Review 10.  Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.